Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions